Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.
Rachel Justus, PharmD, BCPS
Advertisement
Articles by Rachel Justus, PharmD, BCPS
Advertisement
Latest Updated Articles
The Role of PARP Inhibitors in Treating Ovarian CancerApril 30th 2020
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
4
ADA 2026: The 2026 ADA Standards – A Pharmacist's Guide to Cardiorenal Risk Reduction
5